MLH1 and hereditary neoplastic syndrome: These pathways contained 73.6% (82/111) of clinically actionable genes from the ACMG secondary findings list [28] (Figure S2C), particularly those associated with hereditary tumor syndromes (e.g., MLH1, BRCA1, BRCA2, and MSH2) [29] and cardiovascular disorders.